Venous thromboembolism risk with contemporary lenalidomide-based regimens despite thromboprophylaxis in multiple myeloma: A systematic review and meta-analysis
Chakraborty R, Bin Riaz I, Malik SU et Al.
CARDIONCOLOGY.ORG ABSTRACT:
Lenalidomide-based treatment for multiple myeloma can substantially increase the risk of venous thromboembolism (VTE).
This study used meta-analysis to estimate the incidence of VTE when using lenalidomide-based regimens with concurrent thromboprophylaxis to treat myeloma.
The authors conclude that despite thromboprophylaxis, lenalidomide-based regimens have a substantial risk of VTE in controlled clinical trial settings.
© All Rights Reserved